Stockscreener 앱 받기
3.99
11.76%
0.42
시간 외 거래:
1.90
-2.09
-52.38%
Exicure Inc 주식(XCUR)의 최신 뉴스
(XCUR) Risk Channels and Responsive Allocation - Stock Traders Daily
XCUR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
David Giljohann - Crain's Chicago Business
XCUR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Exicure (XCUR) CAO has shares withheld to cover RSU taxes - Stock Titan
Exicure Announces New CEO and Interim CFO Appointments - The Globe and Mail
Exicure appoints Jung Soo Kim as CEO and president - marketscreener.com
Bear Alert: Whats the fair value of Exicure Inc stockFed Meeting & AI Driven Price Forecasts - baoquankhu1.vn
Can Exicure Inc. continue delivering strong returnsWeekly Trade Summary & Weekly High Return Opportunities - mfd.ru
Market Pulse: Does Exicure Inc stock have upside surprise potentialJuly 2025 WrapUp & Smart Allocation Stock Reports - baoquankhu1.vn
Exicure announces board and executive changes, CEO and CFO resignations By Investing.com - Investing.com India
Exicure announces board and executive changes, CEO and CFO resignations - Investing.com Nigeria
Exicure Announces Major Leadership and Board Restructuring - TipRanks
Leadership shake-up at Exicure (NASDAQ: XCUR) as CEO, CFO and directors exit - Stock Titan
Why Exicure Inc. stock remains on watchlistsJuly 2025 Trends & Technical Pattern Recognition Alerts - mfd.ru
Can Exicure Inc. stock sustain revenue growth2025 Stock Rankings & Accurate Buy Signal Alerts - mfd.ru
Aug Intraday: What is the Moat Score of Exicure IncTrade Risk Summary & Capital Protection Trading Alerts - baoquankhu1.vn
Exicure announces publication of results from Phase 2 study of burixafor - TipRanks
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Bur - GuruFocus
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Burixafor - GuruFocus
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - The Manila Times
Exicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease Treatment - Quiver Quantitative
Same-day stem cell collection seen in Exicure Phase 2 cancer trial - Stock Titan
Market Catalysts: Can Exicure Inc expand into new marketsJuly 2025 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Quarterly Earnings: Should I invest in NEPH before earningsWeekly Market Outlook & Daily Profit Maximizing Tips - baoquankhu1.vn
Jobs Data: Does Exicure Inc offer margin of safetyGap Up & Verified Entry Point Detection - baoquankhu1.vn
Trade Report: What is the Moat Score of Exicure Inc2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Market Trends: What is the Moat Score of Exicure IncJuly 2025 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Exicure completes Phase 2 trial milestone and plans $1 million payment to GPCR Therapeutics - Investing.com UK
Exicure to Pay GPCR Therapeutics $1 Million for First Milestone Completion - 아시아경제
Exicure Achieves Milestone in Burixafor Phase 2 Program - TipRanks
Exicure Achieves First Milestone in Collaboration with GPCR Therapeutics - TradingView
Exicure to present phase 2 burixafor data at 2026 transplantation meeting - Investing.com Nigeria
Major Exicure Stakeholder Makes Bold Move With Large Share Sale - TipRanks
Insider Sell: Hitron Exicure Sells 258,367 Shares of Exicure Inc (XCUR) - GuruFocus
Exicure HiTron sells shares worth $1.16 million By Investing.com - Investing.com Nigeria
Exicure HiTron sells shares worth $1.16 million - Investing.com
Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings - TipRanks
Exicure (XCUR) to Showcase Phase 2 Trial Data on Burixafor at 20 - GuruFocus
Exicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem Meetings - Quiver Quantitative
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - The Manila Times
Exicure to Present Data From Burixafor Phase 2 Trial at the 2026 Tandem Meetings - 富途牛牛
Major Exicure Stakeholder Makes a Big Move With a Multi-Million Dollar Stock Sale - TipRanks
Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock By Investing.com - Investing.com Nigeria
Signal Recap: Whats the outlook for Exicure Incs sectorWeekly Trade Report & AI Based Buy and Sell Signals - baoquankhu1.vn
Insider Sell Alert: Hitron Exicure Sells 734,747 Shares of Exicu - GuruFocus
Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock - Investing.com
3.69%
0.68%
자본화:
|
볼륨(24시간):